Coya Therapeutics, Inc. (COYA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 66.27%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 66.27% | Share-based compensation / revenue. Period ending 2026-06-30. $5.31M ÷ $8.02M × 100 ≈ 66.27% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 8.02M USD | |
| Stock-based compensation | 5.31M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -23.15M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.02M | $5.31M | $-23.15M | (m) | (m) | 66.27% | (m) | (m) |
| 2026-03-31 | (m) | $7.94M | $5.41M | $-22.52M | (m) | (m) | 68.09% | (m) | (m) |
| 2025-12-31 | (m) | $7.95M | $4.29M | $-22.56M | (m) | (m) | 54.00% | (m) | (m) |
| 2025-09-30 | (m) | $3.99M | $3.98M | $-20.60M | (m) | (m) | 99.74% | (m) | (m) |
| 2025-06-30 | (m) | $423.45K | $3.68M | $-22.62M | (m) | (m) | 869.37% | (m) | (m) |
| 2025-03-31 | (m) | $3.69M | $3.31M | $-19.44M | (m) | (m) | 89.77% | (m) | (m) |
| 2024-12-31 | (m) | $3.55M | $2.66M | $-17.25M | (m) | (m) | 74.94% | (m) | (m) |
| 2024-09-30 | (m) | $9.55M | $2.11M | $-11.35M | (m) | (m) | 22.09% | (m) | (m) |
| 2024-06-30 | (m) | $9.55M | $1.60M | $-10.47M | (m) | (m) | 16.73% | (m) | (m) |
| 2024-03-31 | (m) | $6.13M | $1.13M | $-10.49M | (m) | (m) | 18.40% | (m) | (m) |
| 2023-12-31 | (m) | $6.00M | $872.25K | $-7.90M | (m) | (m) | 14.53% | (m) | (m) |
| 2023-09-30 | (m) | (m) | $705.68K | $-11.72M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $512.76K | $-10.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $366.31K | $-11.01M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $207.35K | $-9.81M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $233.22K | $-4.87M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |